WO2007132026A1 - Bone-regenerating substance composed of semi-hydrated calcium sulphate and calcium phosphate - Google Patents
Bone-regenerating substance composed of semi-hydrated calcium sulphate and calcium phosphate Download PDFInfo
- Publication number
- WO2007132026A1 WO2007132026A1 PCT/ES2006/000240 ES2006000240W WO2007132026A1 WO 2007132026 A1 WO2007132026 A1 WO 2007132026A1 ES 2006000240 W ES2006000240 W ES 2006000240W WO 2007132026 A1 WO2007132026 A1 WO 2007132026A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bone
- calcium phosphate
- semi
- calcium
- substance composed
- Prior art date
Links
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 title claims abstract description 16
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 14
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 14
- 235000011010 calcium phosphates Nutrition 0.000 title claims abstract description 14
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 13
- 239000000126 substance Substances 0.000 title claims abstract description 10
- 235000011132 calcium sulphate Nutrition 0.000 title claims abstract description 8
- 239000001175 calcium sulphate Substances 0.000 title claims abstract description 6
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 15
- 230000010478 bone regeneration Effects 0.000 claims abstract description 7
- 230000018109 developmental process Effects 0.000 claims description 2
- 230000001172 regenerating effect Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 12
- 230000000278 osteoconductive effect Effects 0.000 abstract description 4
- 230000002421 anti-septic effect Effects 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 2
- 230000003000 nontoxic effect Effects 0.000 abstract description 2
- 230000002138 osteoinductive effect Effects 0.000 abstract description 2
- 150000002484 inorganic compounds Chemical group 0.000 abstract 1
- 229910010272 inorganic material Inorganic materials 0.000 abstract 1
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 description 5
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 description 2
- 235000011151 potassium sulphates Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- -1 phosphate anion Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000000614 rib Anatomy 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00179—Ceramics or ceramic-like structures
- A61F2310/00293—Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
Definitions
- the present invention relates to a substance, composed of calcium sulfate hemihydrate and calcium phosphate.
- the substance, to which the present invention refers, acts as a bone regenerator, both for its application in stomatology, traumatology and in any other medical specialty that requires bone regeneration, traumatology for its development.
- the bone regeneration process involves the following stages: 1.- Activation of osteogenic precursor cells. 2.- Active bone absorption, resorption. 3.- Rest period and 4.- New bone formation.
- osteoblasts bone-producing cells
- the osteoclastic absorption lagoons are repopulated by a contingent of osteoblasts that make osteoid (young bone), which calcifies, the bone being restored.
- For osteogenesis to exist it is necessary that the tissue from which the bone is formed is very vascularized, so that vessels can grow inside blood.
- the products that are used for bone regeneration can be classified into two large groups: Organic or inorganic or synthetic.
- the oldest of the synthetic products used is calcium phosphate, since the body transforms that product into bone tissue.
- the proportion of reabsorption varies and depends on the chemical structure of the material, its porosity and size of the par- title It is osteoconductive.
- B) Calcium sulfate It is soluble in water, a condition lacking calcium phosphate and is, like this one, osteoconductive and, in addition, of great osteoinductive capacity.
- Dr. Dreesman used calcium sulfate as a filler for cavitary defects due to its osteoconductive quality. Resorbable in bone in a shorter time than calcium phosphate (2-3 months).
- the substance in question here composed of calcium sulfate hemihydrate and calcium phosphate, using potassium sulfate as a catalyst, combines the advantages of calcium sulfate hemihydrate and calcium phosphate, that is: it is a porous material, and by therefore of great vascular capacity, of easy reabsorption, containing the phosphate anion and calcium cation necessary for bone neoformation. It is antiseptic and easy to use, not presenting rejection by being inorganic with increased osteoconductivity.
- potassium sulfate in catalytic amounts, to 4%, to accelerate the setting process.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
Abstract
Bone-regenerating substance composed of semi-hydrated calcium sulphate and calcium phosphate, for application in stomatology and traumatology and in any other medical speciality that requires bone regeneration in order to proceed. It is an inorganic compound that, combining the advantages of semi-hydrated calcium sulphate and calcium phosphate, forms a material that is ideal as a bone regenerator, an osteoinductive, or an osteoconductive, and it is reabsorbable, antiseptic, non-toxic and easily handled, in addition to being very economical.
Description
SUSTANCIA REGENERADORA DE HUESO, BONE REGENERATING SUBSTANCE,
COMPUESTA DE SULFATO CALCICO HEMIHIDRATADO Y FOSFATO CALCICO. OBJETO DE LA INVENCIÓN.COMPOUND OF HEMIHYDRATED CALCIUM SULPHATE AND CALCIUM PHOSPHATE. OBJECT OF THE INVENTION
La presente invención se refiere a una sustancia, compuesta de sulfato calcico hemihidratado y fosfato calcico.The present invention relates to a substance, composed of calcium sulfate hemihydrate and calcium phosphate.
La sustancia, a que se refiere la presente invención, actúa como regeneradora del hueso, tanto para su aplicación en estomatología, traumatología como en cualquier otra especialidad médica que requiera para su desarrollo la regeneración ósea, traumatología. ANTECEDENTES DE LA INVENCIÓN.The substance, to which the present invention refers, acts as a bone regenerator, both for its application in stomatology, traumatology and in any other medical specialty that requires bone regeneration, traumatology for its development. BACKGROUND OF THE INVENTION
El proceso de regeneración del hueso implica las siguientes etapas: 1.- Activación de las células osteogénicas precursoras. 2.- Absorción activa del hueso, reabsorción. 3.- Período de descanso y 4.- Formación de hueso nuevo.The bone regeneration process involves the following stages: 1.- Activation of osteogenic precursor cells. 2.- Active bone absorption, resorption. 3.- Rest period and 4.- New bone formation.
La formación de hueso por los osteoblastos, células productoras de la substancia ósea, se da en la zona que ha sido reabsorbida por los osteoclastos. Las lagunas de absorción osteoclástica (lagunas de howship) se repueblan por un contingente de osteoblastos que fabrican osteoide (hueso joven), el cual calcifica, quedando restaurado el hueso. Para que exista la osteogénesis es necesario que el tejido a partir del cual se forme el hueso esté muy vascularizado, para que así puedan crecer en su interior vasos
sanguíneos.Bone formation by osteoblasts, bone-producing cells, occurs in the area that has been reabsorbed by osteoclasts. The osteoclastic absorption lagoons (howship lagoons) are repopulated by a contingent of osteoblasts that make osteoid (young bone), which calcifies, the bone being restored. For osteogenesis to exist it is necessary that the tissue from which the bone is formed is very vascularized, so that vessels can grow inside blood.
En la actualidad, los productos que se utilizan para la regeneración de hueso se pueden clasificar en dos grandes grupos: Orgánicos o inorgánicos o sintéticos.At present, the products that are used for bone regeneration can be classified into two large groups: Organic or inorganic or synthetic.
Dentro de los orgánicos se utilizan:Within the organic ones are used:
A) Injertos procedentes del propio paciente. No producen rechazo, pero implica una actuación quirúrgica en la zona de elección del injerto. Por ejemplo: tibia, fémur, costilla, etc.A) Grafts from the patient himself. They do not produce rejection, but it implies a surgical action in the area of graft choice. For example: tibia, femur, rib, etc.
B) Injertos procedentes de otra persona. Cabe la posibilidad cierta de rechazo, sin descartar el contagio de infecciones. C) Injertos procedentes de animales, principalmente de ganado bovino y equino. Muy utilizados en implantes dentales que, además de producir rechazo, ofrecen la desventaja de que pueden contener priones, lo que exige una exhaustiva esterilización para eliminar esas sustancias, lo que encarece en gran medida el producto y así puedan ser utilizados. No puede descartarse que una deficiente esterilización del material en presencia pueda producir en el paciente efectos indeseables. Dentro de los inorgánicos o sintéticos se utilizan:B) Grafts from another person. There is a certain possibility of rejection, without ruling out the spread of infections. C) Grafts from animals, mainly cattle and horses. Very used in dental implants that, in addition to producing rejection, offer the disadvantage that they can contain prions, which requires an exhaustive sterilization to eliminate these substances, which greatly increases the cost of the product and thus can be used. It cannot be ruled out that poor sterilization of the material in the presence may produce undesirable effects on the patient. Within the inorganic or synthetic are used:
A) El más antiguo de los productos sintéticos utilizados es el fosfato calcico, ya que el organismo transforma ese producto en tejido óseo. La proporción de la reabsorción varía y depende de la estructura química del material, su porosidad y tamaño de la par-
tícula. Es osteoconductivo.A) The oldest of the synthetic products used is calcium phosphate, since the body transforms that product into bone tissue. The proportion of reabsorption varies and depends on the chemical structure of the material, its porosity and size of the par- title It is osteoconductive.
B) El sulfato calcico. Es soluble en agua, condición de la que carece el fosfato calcico y es, al igual que éste, osteoconductor y, además, de gran capacidad osteoinductiva. En 1982, el Dr. Dreesman utilizó el sulfato de calcio como relleno de defectos cavitarios por su cualidad osteoconductora. Reabsorbible en hueso en un tiempo más corto que el fosfato calcico (2-3 meses).
B) Calcium sulfate. It is soluble in water, a condition lacking calcium phosphate and is, like this one, osteoconductive and, in addition, of great osteoinductive capacity. In 1982, Dr. Dreesman used calcium sulfate as a filler for cavitary defects due to its osteoconductive quality. Resorbable in bone in a shorter time than calcium phosphate (2-3 months).
DESCRIPCIÓN DE LA INVENCIÓN La sustancia de la que aquí se trata, compuesta de sulfato calcico hemihidratado y fosfato calcico, utilizando sulfato potásico como catalizador, conjuga las ventajas del sulfato calcico hemihidratado y el fosfato calcico, es decir: resulta un material poroso, y por lo tanto de gran capacidad vascular, de fácil reabsorción, conteniendo el anión fosfato y catión calcico necesarios para la neoformación ósea. Es antiséptico y de fácil manejo, no presentando rechazo al ser inorgánico con osteoconductividad aumentada.DESCRIPTION OF THE INVENTION The substance in question here, composed of calcium sulfate hemihydrate and calcium phosphate, using potassium sulfate as a catalyst, combines the advantages of calcium sulfate hemihydrate and calcium phosphate, that is: it is a porous material, and by therefore of great vascular capacity, of easy reabsorption, containing the phosphate anion and calcium cation necessary for bone neoformation. It is antiseptic and easy to use, not presenting rejection by being inorganic with increased osteoconductivity.
Al mezclar sulfato calcico hemihidratado, que es un material soluble, con fosfato calcico se aumenta la dureza del material y proporciona a los osteoblastos el material necesario para la neoformación de tejido óseo, anión sulfato y catión calcio.Mixing calcium sulfate hemihydrate, which is a soluble material, with calcium phosphate increases the hardness of the material and provides the osteoblasts with the necessary material for bone tissue neoformation, sulfate anion and calcium cation.
A este compuesto se le añade, en el momento de su utilización, sulfato potásico en cantidades catalíticas, al 4%, para acelerar el proceso de fraguado.To this compound is added, at the time of use, potassium sulfate in catalytic amounts, to 4%, to accelerate the setting process.
Esta cristalización acelerada del sulfato y fosfato calcico hace que no se forme una estructura cristalina perfecta, sino que se crean numerosas oquedades en el material. Estos poros forman una serie de cavidades unidas unas con otras, como una esponja, que permite la entrada de capilares sanguíneos en el interior de su estructura, y por tanto la regeneración ósea. Además, como el sulfato calcico hemihidratado es soluble se crean mayores oquedades en el interior del material al estar en contacto con el torrente sanguíneo.
La sustancia, de que se trata esta invención, que se comercializará en cápsulas, al disolverla en el catalizador, presenta una consistencia pastosa de color blanquecino que va endureciendo progresivamente en unos 4 minutos. Transcurrido ese tiempo el material se puede moldear con los dedos y lo podemos colocar, comprimiéndolo con una gasa. De ese modo se obtienen dos efectos: que se adapte perfectamente al defecto óseo y que elimine la sangre de la zona.This accelerated crystallization of sulfate and calcium phosphate means that a perfect crystalline structure is not formed, but that numerous holes in the material are created. These pores form a series of cavities attached to each other, such as a sponge, which allows the entry of blood capillaries inside its structure, and therefore bone regeneration. In addition, as the calcium sulfate hemihydrate is soluble, greater cavities are created inside the material when in contact with the bloodstream. The substance, which is the subject of this invention, which will be marketed in capsules, when dissolved in the catalyst, has a whitish paste consistency that gradually hardens in about 4 minutes. After that time the material can be molded with the fingers and we can place it, compressing it with gauze. In this way two effects are obtained: that it adapts perfectly to the bone defect and that it eliminates blood from the area.
Dejándolo sin tocar se procedería a la sutura de la incisión quirúrgica. Si el material quedase expuesto por falta de cierre de la herida, no ofrece ningún inconveniente, puesto que este producto actúa como barrera y además tiene propiedades bactericidas, por lo que es imposible su contaminación por acción de las bacterias de la zona, al contrario de lo que ocurre con las membranas de origen orgánico. Este nuevo material no necesita membranas. Por otra parte, el sulfato y fosfato calcico tienen un precio muy económico, constituyendo un material ideal como regenerador óseo, ya que al ser reabsorbible, inorgánico, antiséptico, no tóxico y de fácil manejo, hacen de él un material extraordinario para la regeneración ósea.
Leaving it untouched would proceed to suturing the surgical incision. If the material is exposed due to lack of closure of the wound, it does not offer any inconvenience, since this product acts as a barrier and also has bactericidal properties, so it is impossible to contaminate it due to the bacteria in the area, unlike what happens with the membranes of organic origin. This new material does not need membranes. On the other hand, calcium sulphate and phosphate have a very economical price, constituting an ideal material as a bone regenerator, since being reabsorbable, inorganic, antiseptic, non-toxic and easy to use, they make it an extraordinary material for bone regeneration .
Claims
1.- Sustancia regeneradora de hueso, compuesta de sulfato calcico hemididratado y fosfato calcico, mezclados en diversas proporciones, para su aplicación en estomatología, traumatología y en cualquier otra especialidad médica que requiera para su desarrollo la regeneración ósea. 1.- Bone regenerating substance, composed of calcium sulphate hemididratado and calcium phosphate, mixed in various proportions, for application in stomatology, traumatology and in any other medical specialty that requires bone regeneration for its development.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/ES2006/000240 WO2007132026A1 (en) | 2006-05-12 | 2006-05-12 | Bone-regenerating substance composed of semi-hydrated calcium sulphate and calcium phosphate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/ES2006/000240 WO2007132026A1 (en) | 2006-05-12 | 2006-05-12 | Bone-regenerating substance composed of semi-hydrated calcium sulphate and calcium phosphate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2007132026A1 true WO2007132026A1 (en) | 2007-11-22 |
Family
ID=38693568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/ES2006/000240 WO2007132026A1 (en) | 2006-05-12 | 2006-05-12 | Bone-regenerating substance composed of semi-hydrated calcium sulphate and calcium phosphate |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007132026A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4619655A (en) * | 1984-01-26 | 1986-10-28 | University Of North Carolina | Plaster of Paris as a bioresorbable scaffold in implants for bone repair |
| WO1991000252A1 (en) * | 1989-06-30 | 1991-01-10 | United States Gypsum Company | Calcium sulfate hemihydrate composition having utility in the presence of blood |
| WO1991017722A1 (en) * | 1990-05-11 | 1991-11-28 | Lifecore Medical, Inc. | Rapid setting hydroxylapatite and plaster formulation |
| WO2000007639A1 (en) * | 1998-08-07 | 2000-02-17 | Tissue Engineering, Inc. | Bone precursor compositions |
| WO2000027316A1 (en) * | 1998-11-06 | 2000-05-18 | John Ricci | Implantation of surgical implants with calcium sulfate |
| WO2002005861A1 (en) * | 2000-07-17 | 2002-01-24 | Bone Support Ab | A composition for an injectable bone mineral substitute material |
-
2006
- 2006-05-12 WO PCT/ES2006/000240 patent/WO2007132026A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4619655A (en) * | 1984-01-26 | 1986-10-28 | University Of North Carolina | Plaster of Paris as a bioresorbable scaffold in implants for bone repair |
| WO1991000252A1 (en) * | 1989-06-30 | 1991-01-10 | United States Gypsum Company | Calcium sulfate hemihydrate composition having utility in the presence of blood |
| WO1991017722A1 (en) * | 1990-05-11 | 1991-11-28 | Lifecore Medical, Inc. | Rapid setting hydroxylapatite and plaster formulation |
| WO2000007639A1 (en) * | 1998-08-07 | 2000-02-17 | Tissue Engineering, Inc. | Bone precursor compositions |
| WO2000027316A1 (en) * | 1998-11-06 | 2000-05-18 | John Ricci | Implantation of surgical implants with calcium sulfate |
| WO2002005861A1 (en) * | 2000-07-17 | 2002-01-24 | Bone Support Ab | A composition for an injectable bone mineral substitute material |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Combes et al. | Calcium carbonate–calcium phosphate mixed cement compositions for bone reconstruction | |
| Horch et al. | Synthetic, pure-phase beta-tricalcium phosphate ceramic granules (Cerasorb®) for bone regeneration in the reconstructive surgery of the jaws | |
| Xiao et al. | Preparation of resorbable carbonate-substituted hollow hydroxyapatite microspheres and their evaluation in osseous defects in vivo | |
| Berberi et al. | Physicochemical characteristics of bone substitutes used in oral surgery in comparison to autogenous bone | |
| US11628069B2 (en) | 3D printing of polymeric bioceramics for the treatment of bone defects | |
| US20090028954A1 (en) | Precursor for the preparation of a pasty bone replacement material by admixture of a liquid | |
| EP2421543A1 (en) | Dual-phase calcium phosphate cement composition | |
| ES2207827T3 (en) | BONE CEMENT PASTE CONTAINING ANTIBIOTICS. | |
| Masaeli et al. | Efficacy of the biomaterials 3 wt%-nanostrontium-hydroxyapatite-enhanced calcium phosphate cement (nanoSr-CPC) and nanoSr-CPC-incorporated simvastatin-loaded poly (lactic-co-glycolic-acid) microspheres in osteogenesis improvement: An explorative multi-phase experimental in vitro/vivo study | |
| US10172977B2 (en) | Porous biomaterial | |
| PT1829565E (en) | A new bone mineral substitute | |
| Demirel et al. | Effect of strontium-containing compounds on bone grafts | |
| Ebrahimi | Bone grafting substitutes in dentistry: general criteria for proper selection and successful application | |
| Takechi et al. | The in vitro antibiotic release from anti-washout apatite cement using chitosan | |
| Saxena et al. | Calcium phosphate enriched synthetic tyrosine-derived polycarbonate–dicalcium phosphate dihydrate polymer scaffolds for enhanced bone regeneration | |
| Daculsi | Biphasic calcium phosphate granules concept for injectable and mouldable bone substitute | |
| Aqib et al. | Metal-Doped brushite cement for bone regeneration | |
| US20130309214A1 (en) | Composition containing injectable self-hardened apatite cement | |
| Mamidwar et al. | In vitro characterization of a calcium sulfate/PLLA composite for use as a bone graft material | |
| WO2007132026A1 (en) | Bone-regenerating substance composed of semi-hydrated calcium sulphate and calcium phosphate | |
| US20060110422A1 (en) | Conversion of calcite powders into macro- and microporous calcium phosphate scaffolds for medical applications | |
| BRPI0611774A2 (en) | solid precursor for the preparation of a pasty material for bone replacement by mixing a liquid | |
| ES2373137B2 (en) | CEMENT OF CALCIUM-CALCIUM SILICATE PHOSPHATE FOR BIOMEDICAL APPLICATIONS. | |
| Hallman et al. | Bone replacement following dental trauma prior to implant surgery–present status | |
| Straub et al. | Calcium Sulfate Bone Substitutes in Clinical Use: History, Material Properties, Application, and Outlook for the Future |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06743479 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06743479 Country of ref document: EP Kind code of ref document: A1 |